851224-99-2

Upstream product

• 447406-77-1 2-(4-mercapto-2-methyl-phenoxy)-2-methyl-propionic acid ethyl ester 
• 851224-98-1 5-bromomethyl-3-(4-tert-butylphenyl)[1,2,4]thiadiazole 
• 95-48-7 ortho-cresol 
• 851224-95-8 5-(4-tert-butylphenyl)[1,3,4]oxathiazol-2-one 
• 447406-76-0 2-(4-chlorosulfonyl-2-methylphenoxy)-2-methylpropionic acid ethyl ester 
• 851224-97-0 [3-(4-tert-butylphenyl)[1,2,4]thiadiazol-5-yl]methanol 
• 851224-96-9 3-(4-tert-butylphenyl)[1,2,4]thiadiazole-5-carboxylic acid ethyl ester 
• 600-00-0 ethyl 2-bromoisobutyrate 
• 71659-82-0 2-methyl-2-o-tolyloxypropionic acid ethyl ester 
• 56108-12-4 4-tert-butylbenzamide 

Relevant academic research and scientific papers

Synthesis and identification of [1,2,4]thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors α and δ

Cardiovascular disease is the most common cause of morbidity and mortality in developed nations. To effectively target dyslipidemia to reduce the risk of cardiovascular disease, it may be beneficial to activate the peroxisome proliferator-activated recept

4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.